Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions, announced significant engagement from orthopedic surgeons and cartilage specialists at the 8th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit, held October 8-10 in Porto, Portugal. The discussions centered on GelrinC®, the company’s CE Mark-approved, cell-free hydrogel implant designed to regenerate damaged knee cartilage in a single procedure lasting about 10 minutes.
According to the company, a Phase II study showed that GelrinC achieved approximately 100% greater improvement in overall Knee Injury and Osteoarthritis Outcome Score (KOOS) compared with historical microfracture controls at two years. Subsequent MRI analyses indicated results consistent with durable, native-like cartilage regeneration. These clinical outcomes, combined with the procedure’s efficiency, are driving interest among physicians seeking better options for cartilage repair.
Regentis is working to convert this interest into broader clinical adoption through its expanding European Centers of Excellence while advancing its ongoing U.S. Food and Drug Administration pivotal trial. The company aims to address a U.S. market of approximately 470,000 cartilage knee repair cases annually, where no off-the-shelf treatment is currently available. GelrinC’s cell-free, off-the-shelf nature could streamline surgical workflows and improve patient outcomes, making it a potentially disruptive force in orthopedic care.
For investors, the strong surgeon engagement at a premier international summit signals growing validation of GelrinC’s technology and may accelerate commercial traction in Europe. The progress of the U.S. pivotal trial is also critical, as a successful outcome could open the door to the largest cartilage repair market globally. The company’s ability to execute on both fronts will be key to capturing a significant share of this underserved market.
The full press release is available at https://ibn.fm/hcEu4. The latest news and updates relating to RGNT can be found in the company’s newsroom at https//ibn.fm/RGNT.
InvestorWire, a specialized communications platform, disseminated the announcement. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit InvestorWire. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
